drugset / Trial / NCT07100873
A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
RandomizedParallel-groupSingle-blindTreatment
Summary
ADI-001-106 is a phase 1 study of ADI-001 with a randomized, single-blind, parallel group design to compare two different LD regimens in subjects with treatment-refractory RA. The study will consist of different periods including screening, LD, treatment, and follow-up
Timeline
- Start
- 2025-10-10
- Primary completion
- 2027-03-30
- Completion
- 2028-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADI-001 | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |